Trinidad, Camille V. http://orcid.org/0000-0003-3480-208X
Pathak, Harsh B. http://orcid.org/0000-0003-4034-0520
Cheng, Shibo http://orcid.org/0009-0002-2400-8245
Tzeng, Shin-Cheng http://orcid.org/0000-0002-1095-7418
Madan, Rashna
Sardiu, Mihaela E. http://orcid.org/0000-0002-3987-7569
Bantis, Leonidas E. http://orcid.org/0000-0002-2364-2562
Deighan, Clayton
Jewell, Andrea http://orcid.org/0000-0002-4752-6662
Rayamajhi, Sagar
Zeng, Yong
Godwin, Andrew K. http://orcid.org/0000-0002-3987-9580
Funding for this research was provided by:
OVERRUN Ovarian Cancer Foundation
NIH National Cancer Institute (R01 CA260132)
Kansas Institute for Precision Medicine (GM130423)
Honorable Tina Brozman Foundation, Inc.
Predicine Inc.
Article History
Received: 13 April 2023
Accepted: 3 October 2023
First Online: 26 October 2023
Competing interests
: A.K.G. is a co-founder of Sinochips Diagnostics, serves as a scientific advisory board member to Biovica, Clara Biotech, and Sinochips Diagnostics, and receives research funding from Predicine and VITRAC Therapeutics. Y.Z. serves as a scientific advisory board member to Clara Biotech. C.V.T., H.B.P, M.E.S. and A.K.G applied to patent ACSL4, IGSF8, ITGA2, ITGA5, ITGB3 and MYOF as early detection biomarkers for ovarian cancer. The other authors report no conflict of interest.